SCHEMBL6501879

SCHEMBL6501879

CC(=O)NCC1CN(c2ccc(N3CCN(C(=O)c4ccco4)CC3)c(F)c2)C(=O)O1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.69
MAOA P21397 5/20 0.69
PTGS1 P23219 2/20 0.69
SDHA P31040 2/20 0.69
LMNA P02545 1/20 0.69
CALML3 P27482 1/20 0.69
MEN1 O00255 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.56
NPC1 O15118 1/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
F10 P00742 4/20 0.54
TOP2B Q02880 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10152368 0.91 MAOB (0.71) MAOBMAOAPTGS1SDHALMNA
SCHEMBL10151569 0.89 MAOA (0.63) MAOBMAOAPTGS1SDHALMNA
SCHEMBL13938323 0.88 MAOB (0.66) MAOBMAOAPTGS1SDHALMNA
SCHEMBL5412052 0.87 MAOB (0.73) MAOBMAOAPTGS1SDHALMNA
SCHEMBL5412059 0.87 MAOB (0.73) MAOBMAOAPTGS1SDHALMNA
SCHEMBL1894511 0.86 MAOB (0.79) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6614867 0.86 MAOB (0.79) MAOBMAOAPTGS1SDHALMNA
SCHEMBL14448235 0.85 MAOB (0.67) MAOBMAOAPTGS1SDHALMNA
SCHEMBL8307285 0.85 MAOB (0.78) MAOBMAOAPTGS1SDHALMNA
SCHEMBL6551656 0.85 MAOB (0.78) MAOBMAOAPTGS1SDHALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956040-B2 Oxazolidinone piperazinyl derivatives as potential antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2005-10-18 US claimed
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2004-12-16 US claimed
EP-1409465-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2004-04-21 EP claimed
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials MEHTA ANITA (IN) 2003-06-26 US claimed
EP-1303511-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2003-04-23 EP claimed
WO-2003007870-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2003-01-30 WO claimed
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease RANBAXY LABORATORIES LIMITED (IN) 2002-08-01 US claimed
WO-2002006278-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2002-01-24 WO claimed
US-6956040-B2 Oxazolidinone piperazinyl derivatives as potential antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2005-10-18 US disclosed
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials RANBAXY LABORATORIES LIMITED (IN) 2004-12-16 US disclosed
US-6734307-B2 USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING RANBAXY LABORATORIES LIMITED (IN) 2004-05-11 US disclosed
EP-1409465-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2004-04-21 EP disclosed
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials MEHTA ANITA (IN) 2003-06-26 US disclosed
EP-1303511-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES, LTD. (IN) 2003-04-23 EP disclosed
WO-2003007870-A2 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2003-01-30 WO disclosed
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease RANBAXY LABORATORIES LIMITED (IN) 2002-08-01 US disclosed
WO-2002006278-A1 OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS RANBAXY LABORATORIES LIMITED (IN) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119817-A1 Oxazolidinone derivatives as potential antimicrobials OXA1L, PDK4, SDHA MAOB 1887/4885MAOA 1651/4885PTGS1 3290/4885
US-20020103186-A1 Oxazolidinone derivatives as antimicrobials disease OXA1L, MLYCD, TBCD MAOB 1453/4885MAOA 829/4885PTGS1 2806/4885
US-20040254162-A1 Oxazolidinone derivatives as antimicrobials PPARD, PDK4, OXA1L MAOB 2293/4885MAOA 1874/4885PTGS1 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.